Introduction/Overview
Cucurbitacin IIb (CAS number: 50298-90-3) is a highly oxidized natural product of tetracyclic triterpenoids, mainly found in plants of the Cucurbitaceae family. As an important member of the Xue Dan Su family, Xue Dan Su Yi has attracted widespread attention in the field of natural product pharmacology in recent years due to its significant biological activity and multi-target regulatory ability. Numerous studies have shown that Xuedan B not only exhibits significant anti-cancer activity, especially in solid tumor models such as liver cancer, but also has multiple pharmacological effects such as anti-inflammatory, antioxidant, antiviral, hypoglycemic, hepatoprotective, and neuroprotective effects. Its oral activity and multi-target mechanism of action provide a solid foundation for its potential as a drug molecule.
This article provides a systematic review of the chemical structure, sources, extraction methods, pharmacological activities, and mechanisms of action of Xuedansu B, with a focus on its molecular targets and signaling pathway regulation in the treatment of liver cancer. Combining drug parameters and pharmacokinetic characteristics, it explores its clinical application prospects and development directions, aiming to provide theoretical reference and practical guidance for subsequent related research and drug development.
Chemical structure and physicochemical properties
Xuedansu B belongs to the tetracyclic triterpenoid class, with a molecular formula of C ∝₂ H ₄₄ O ₈ and a molecular weight of 520.7000. Its structural characteristics include a highly oxidized tetracyclic skeleton with multiple hydroxyl and ketone functional groups, endowing it with strong polarity and biological activity. The LogP value of Xuedan B is about 3.24, indicating that it has moderate lipid solubility, which is beneficial for cell membrane penetration and in vivo distribution. The polar surface area (TPSA) is 126.98 Å ², indicating its good solubility in polar environments and the presence of a large number of hydrogen bond acceptors (7), which helps it form stable binding with biomolecule targets.
From a pharmacokinetic perspective, the blood-brain barrier permeability of Xuebilin B is relatively low, indicating its limited distribution in the central nervous system. This may have certain limitations on the neuroprotective effect, but it also reduces the risk of central nervous system toxicity. Hepatotoxicity and cardiotoxicity are not yet clear, and the hERG channel inhibition experiment results are negative, indicating good cardiac safety. The results of Ames mutagenicity test have not been reported yet, and further evaluation of its genotoxicity risk is needed.
Plant sources and extraction methods
Xuedan B is mainly distributed in Cucurbitaceae plants, especially in traditional Chinese medicinal herbs such as Momordica charantia, Trichosanthes kirilowii, and Cucurbita spp., where it is abundant. These plants are widely cultivated and studied for their medicinal and nutritional value.
The common methods for extracting Snow Gallbladder B include solvent extraction, ultrasound assisted extraction, and column chromatography separation. Generally, ethanol or methanol is used as the extraction solvent, and purification is carried out by cold soaking or heating reflux extraction, combined with liquid-liquid distribution and silica gel column chromatography. In recent years, supercritical CO ₂ extraction technology has also been applied to improve extraction efficiency and purity. High performance liquid chromatography (HPLC) and mass spectrometry (LC-MS) are widely used for the qualitative and quantitative analysis of berberine B.
The optimization of extraction process not only affects the yield and purity of Xuedan B, but also determines its subsequent pharmacological activity. The establishment of standardized extraction process and quality control system is a key step in achieving the clinical application of Xuebilin B.
Pharmacological activity research
anticancer activity
Xuedan B has shown significant anti-tumor activity in various cancer models, especially in liver cancer cell lines where research is most in-depth. It mainly manifests as inhibiting the proliferation, migration, and invasion of cancer cells, while inducing cell cycle arrest and promoting apoptosis. In vitro experiments have shown that Xuebilin B can significantly reduce the survival rate of liver cancer cells, inhibit their migration ability, reduce the expression of matrix metalloproteinase (MMP9), and thus weaken the invasiveness of tumors.
In addition, Xuedan B intervenes in the survival and metastasis mechanisms of tumor cells by regulating multiple signaling pathways, such as STAT3, PI3K/AKT, NF - κ B. Animal model studies further confirmed its anti-tumor effect, showing a significant reduction in tumor volume and an increase in tumor cell apoptosis rate.
Anti inflammatory and antioxidant effects
Inflammatory response is an important mechanism for the occurrence and development of various diseases. Xuedan B exhibits good anti-inflammatory effects by inhibiting the NF - κ B signaling pathway and reducing the expression of pro-inflammatory factors such as TNF - α and IL-6. Its antioxidant activity is mainly reflected in clearing reactive oxygen species (ROS) and regulating antioxidant enzyme activity, reducing oxidative stress damage, and protecting cellular function.
These characteristics make Xue Dan Su B have potential therapeutic value in chronic inflammatory diseases and oxidative stress-related diseases.
Antiviral and hypoglycemic effects
Xuedan B exhibits certain inhibitory effects on various viruses, possibly by interfering with virus replication and regulating host immune responses. Although the specific mechanism still needs further research, its broad-spectrum antiviral potential provides new ideas for the development of novel antiviral drugs.
In the field of metabolic diseases, Xuedan B has shown effects in improving insulin resistance and lowering blood sugar, suggesting that it may exert hypoglycemic effects by regulating signaling pathways related to glucose and lipid metabolism.
Liver protection and neuroprotective effects
The liver, as an important organ for metabolism and detoxification, is susceptible to various types of damage. Xuedansu B exhibits significant hepatoprotective effects by anti-inflammatory, antioxidant, and regulating cell apoptosis, which can alleviate liver damage and promote liver cell repair.
In terms of neuroprotection, Xuedan B has shown potential neuroprotective value by inhibiting neuroinflammation and reducing oxidative stress, protecting neurons from damage, especially in the research of neurodegenerative diseases.
Mechanism of action and molecular targets
The multi-target mechanism of action of Xuedan B is the basis for its various pharmacological effects. For liver cancer, the main targets include:
- BCL2 Xuedan B promotes cancer cell apoptosis and disrupts cell survival balance by downregulating the expression of anti apoptotic protein BCL2.
- STAT3 As a key transcription factor, STAT3 regulates various tumor related genes. Xuedan B inhibits the phosphorylation and nuclear translocation of STAT3, blocks its signal transduction, and suppresses tumor growth and metastasis.
- TOP1 Xuedan B may interfere with the activity of DNA topoisomerase I (TOP1), affecting DNA replication and repair processes, leading to tumor cell death.
- TERT Telomerase reverse transcriptase (TERT) is a key factor in the unlimited proliferation of tumor cells. Xuedan B inhibits TERT expression and limits the proliferation potential of tumor cells.
- PIK3CA/AKT1 The PI3K/AKT signaling pathway plays a central role in tumor cell proliferation and survival. Xuedan B inhibits the activity of PIK3CA and AKT1, blocks this pathway, and promotes cell cycle arrest and apoptosis.
- MMP9 As a matrix degrading enzyme, MMP9 promotes the migration and invasion of tumor cells. Xuedan B inhibits MMP9 expression and reduces tumor metastasis ability.
- EGFR The epidermal growth factor receptor (EGFR) is involved in the proliferation and survival of tumor cells. The regulation of the EGFR signaling pathway by Xuedan B helps to inhibit tumor progression.
- TP53 As a tumor suppressor gene, the activation of TP53 promotes cell cycle arrest and apoptosis. Xuedan B may enhance anti-tumor effects by regulating TP53 related pathways.
- NFKB1 The NF - κ B signaling pathway plays an important role in inflammation and tumors. Xuedan B inhibits NFKB1 activity, reduces inflammatory response, and suppresses tumor growth.
Overall, Xuedan B exhibits strong anti-tumor potential by synergistically regulating tumor cell proliferation, apoptosis, migration, and invasion through multiple targets and pathways.
Evaluation of drug properties and pharmacokinetics
The molecular weight of Xuedansu B is 520.7, which belongs to the category of medium molecular weight compounds. The LogP value of 3.24 shows that it has moderate lipid solubility and meets the lipid solubility requirements of oral drugs. The TPSA is 126.98 Å ², which is relatively high but still within an acceptable range, indicating that it has a certain degree of bioavailability.
Its hydrogen bond receptor number is 7, which may affect membrane permeability, but combined with its oral activity, it indicates that it has good absorption and distribution characteristics in vivo. The low permeability of the blood-brain barrier reduces the risk of central nervous system side effects, but limits its application in central nervous system diseases.
In terms of safety, the hERG inhibition test was negative, indicating a low risk of cardiac toxicity, but liver toxicity and genotoxicity are not yet clear and require further systematic evaluation. There is a lack of systematic reports on pharmacokinetic parameters such as metabolic pathways and half-life in vivo. Future research should focus on their metabolic stability, in vivo distribution, and excretion pathways.
Overall, Xuedansu B has a good pharmacological basis, but further pharmacokinetic and toxicological studies are still needed to support its clinical development.
Clinical application prospects and prospects
Xuedansu B has demonstrated extensive clinical application potential due to its multi-target and multi effect pharmacological properties. Its advantages in the treatment of liver cancer are particularly prominent, as it can synergistically inhibit tumor progression through multiple signaling pathways and has the potential to develop into a new type of anti-tumor drug.
In addition, its anti-inflammatory, antioxidant, and hepatoprotective effects provide new treatment ideas for chronic liver disease and inflammatory diseases. The antiviral and hypoglycemic effects have expanded its application prospects in the fields of infectious diseases and metabolic diseases. The neuroprotective effect provides the possibility for adjuvant therapy of neurodegenerative diseases.
Future research should focus on:
- In depth analysis of the mechanism Using modern molecular biology and omics techniques, further clarify the molecular action network and signaling pathway regulation mechanism of Xuebilin B.
- Pharmacokinetic and safety evaluation The system conducts in vivo metabolism, toxicology, and long-term safety research to ensure the safety and effectiveness of clinical applications.
- Formulation development and optimization of administration routes Explore new technologies such as nanocarriers and sustained-release formulations to improve their bioavailability and targeting.
- Preclinical and clinical research Conduct systematic animal model validation and early clinical trials to evaluate its efficacy and safety, and promote its clinical translation.
Combining interdisciplinary research, Xuebilin B is expected to become an important candidate molecule for the development of natural anti-cancer and multifunctional drugs.
Conclusion
Xuedansu B, as a highly oxidized natural product of tetracyclic triterpenoids, exhibits a wide range of biological activities and good medicinal properties due to its multi-target and multi effect pharmacological properties. Especially in the field of liver cancer treatment, it significantly inhibits tumor proliferation, migration, and invasion, promotes apoptosis, and demonstrates strong anti-tumor potential by regulating key molecular targets and signaling pathways.
Although there is currently incomplete data on its pharmacokinetics and safety, its oral activity and multiple pharmacological effects have laid a solid foundation for subsequent drug development. In the future, through systematic mechanism research, pharmacokinetic evaluation, and clinical validation, Xuedan Yi is expected to become an important representative of natural anti-cancer drugs and multifunctional therapeutic agents.
In summary, Xuedansu B not only enriches the research content of natural product pharmacology, but also provides new strategies and directions for the treatment of liver cancer and related diseases, with broad scientific research and clinical application prospects.
